ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EDSA Edesa Biotech Inc

4.5141
-0.0359 (-0.79%)
09 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Edesa Biotech Inc NASDAQ:EDSA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0359 -0.79% 4.5141 3.66 5.08 4.68 4.51 4.68 4,851 21:06:40

Form 8-K - Current report

26/10/2023 1:01pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 25, 2023

 

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

British Columbia, Canada

001-37619

N/A

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

100 Spy Court

Markham, Ontario, Canada L3R 5H6

(Address of Principal Executive Offices)

 

(289) 800-9600

Registrant’s telephone number, including area code

 

N/A

 (Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of exchange on which registered

Common Shares

 

EDSA

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 Item 8.01. Other Events.

 

On October 25, 2023, Edesa Biotech, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company’s common shares, no par value per share (the “Common Shares”), had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed.

 

As previously reported, on June 22, 2023, the Company received a letter from Nasdaq’s Listing Qualifications Staff indicating that, based upon the closing bid price of the Common Shares for the last 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). Pursuant to the Notice, Nasdaq had given the Company 180 calendar days, or until December 19, 2023, to regain compliance with the Minimum Bid Price Requirement.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

EDESA BIOTECH, INC.

 

 

 

 

 

Dated: October 26, 2023

By:

/s/ Stephen Lemieux

 

 

Name:

Stephen Lemieux

 

 

Title:

Chief Financial Officer

 

 

 

 

 

v3.23.3
Cover
Oct. 25, 2023
Cover [Abstract]  
Entity Registrant Name Edesa Biotech, Inc.
Entity Central Index Key 0001540159
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Oct. 25, 2023
Entity File Number 001-37619
Entity Incorporation State Country Code A1
Entity Address Address Line 1 100 Spy Court
Entity Address City Or Town Markham
Entity Address State Or Province ON
Entity Address Country CA
Entity Address Postal Zip Code L3R 5H6
City Area Code 289
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Local Phone Number 800-9600
Security 12b Title Common Shares
Trading Symbol EDSA
Security Exchange Name NASDAQ

1 Year Edesa Biotech Chart

1 Year Edesa Biotech Chart

1 Month Edesa Biotech Chart

1 Month Edesa Biotech Chart

Your Recent History

Delayed Upgrade Clock